Sue Dehnam

Senate Democrats have revived CAOA, a sweeping bill that would deschedule cannabis entirely and address several consequences of federal prohibition. Its previous versions went nowhere.

Most of the 21 hemp THC beverages tested by a nonprofit missed their label claims, adding an inconvenient new wrinkle to the industry’s argument for regulation instead of prohibition.

Trulieve will begin trading on the NYSE after executing a strategic corporate restructuring to maintain a 100-percent medical consolidated footprint.

Curaleaf Holdings is making its most tangible move yet toward a major U.S. stock exchange listing with a reverse split of its subordinate shares.

Splash Beverage Group (NYSE: SBEV) appoints Sunburn Cannabis CEO Brady Cobb to lead its strategic pivot from alcohol to the high-growth cannabinoid and regulated wellness sectors.

In a move that signals massive consolidation in the B2B events space, Apollo Global Management has agreed to acquire Emerald Holding Inc. — parent company of MJBizCon — in a $1.5-billion all-cash deal. The transaction will take the publicly traded Emerald private, merging its portfolio with Questex LLC to create a unified experiential media platform. While the deal reflects Apollo’s broader interest in specialized markets rather than a specific cannabis play, the shift raises critical questions about the future of the industry’s largest trade show. Will MJBizCon thrive under new institutional ownership, or drift within a larger, more diverse portfolio?

The DEA isn’t stepping back; it’s stepping in. While the industry celebrates the end of 280E, the fine print of the new Schedule III order reveals a mandatory federal middleman, undisclosed fees, and a legal “prescription” trap that could leave dispensaries in limbo. Here is what the rescheduling order actually means for your bottom line.

WEST HOLLYWOOD, Calif. – The cannabis industry is quick to celebrate sales figures and product launches, the popular players, and celebrity partnerships. Less often...

ASA launches the Navarro Family Organ Transplant Resource Center to provide tools and advocacy for medical cannabis patients facing transplant discrimination.

Following a series of SEC penalties, executive shifts, and a failed bid to go private, Weedmaps’ parent company prepares to transition to the OTC Markets.